MATTHEW L ANDERSON, MD
Medical Practice at Main St, Houston, TX

6434857, Aug 20, 2002

Jul 5, 2000

09/610035

Robert David Anderson - Wichita Falls TX
Matthew David Anderson - Houston TX

SmartClean JV - Wichita Falls TX

F26B 1102

34595, 34 74, 34 75, 34 77, 34 80, 34128, 34473, 68 13, 68 19, 68 20

A combination closed-circuit washer and drier apparatus having a washing cycle and a drying cycle. The apparatus comprises a unitary housing having a tub and a tumbler within the tub, the tub also having an air inlet and air outlet which allows air to flow through the tub, wherein air flowing from the air inlet is in communication with the tumbler. The apparatus also includes a desiccant recharging system located within the unitary housing having a entrance and an exit, the entrance coupled to the air outlet and the exit coupled to the air entrance, thus allowing a continuous flow of air through the system. The desiccant recharging system also includes a diverting valve that directs the flow of air primarily through the desiccant system in a closed-loop during the wash cycle. The diverting valve alters the air flow between the washing cycle (desiccant regeneration) to the drying cycle (desiccant water adsorption).

2012002, Feb 2, 2012

Aug 2, 2011

13/136498

Preethi H. Gunaratne - Houston TX, US
Lalithya C. Jayarathne - Houston TX, US
Matthew L. Anderson - Houston TX, US

A61K 31/7088, C12N 5/02, A61P 35/00, C07H 21/04, C07H 21/02, C07F 1/12, C12Q 1/02, A61K 31/28

514 44 R, 435 29, 435375, 514495, 536 231, 536 245, 556 28, 556111

Provided herein are nanoparticle platforms and combinatorial drug delivery vehicles comprising gold nanoparticles with a plurality of thilolated hyperbranched dendrons conjugated to the nanoparticle surface. The thiolated hyperbranched dendrons comprise chemically-modifiable surface groups, functionalized interior groups and nano-cavities within the hyperbranched structure to which a variety of payload molecules may be conjugated, optionally via a linker. Payload molecules may comprise nucleic acids, anticancer drugs and small molecule inhibitors, optionally with, non-cytotoxic signaling agents, for example, fluoroscein isothiocyanate. Also provided are methods for delivering one or more therapeutic agents to a cell or tissue or for treating a pathophysiological condition in a subject by delivering the combinatorial drug delivery vehicles to a cell or tissue associated with the pathophysiological condition to facilitate internalization of the vehicle to effect treatment.

2013006, Mar 14, 2013

Oct 14, 2010

13/501806

Martin M. Matzuk - Houston TX, US
Chad Creighton - Houston TX, US
Zhifeng Yu - Houston TX, US
Michael Fountain - Houston TX, US
Preethi Gunaratne - Houston TX, US
Matthew A. Anderson - Houston TX, US

Baylor College of Medicine - Houston TX

A61K 31/7088, A61P 35/00

514 44 R

The present invention generally concerns methods and compositions for treating and/or preventing cancer with microRNAs. In specific embodiments, the present invention encompasses a particular microRNA, microRNA-31, as useful in cancer therapy and/or prevention. Specific cancers may be treated, including at least ovarian, prostate, urothelial, osteosarcoma, and glioblastoma.